(i.e. there is no repair ofdamage). B, exponential doseresponse curve with shoulder derivedfrom Fig A, assuming that a cell can repair the damage due to one hit but is inactivated by two hits. c, hyperbolic type of dose-response curve derivedfrom Fig IB   more than once, the less the chance of complete repair, and the greater the resulting effect. Evidently, with agents giving this type of doseresponse curve, it pays to give massive doses.
The converse is true in Fig 2c. In the high dose range, large increments in dose produce relatively little increase in effect. The greatest ireturn for dose administered is in the lower dose range. Accordingly, if one compares various dose regimens in which the same total amount of drug is given over the same period, antimetabolites will tend to have more effect if the doses are small and frequent, while alkylating agents are likely to have more effect if doses are massive and few. When the curve is like that in Fig 2A, as it is sometimes with radiation and alkylating agents, the total effect should be independent of the manner of dose division.
Although these considerations tell us something about effects on proliferating cells in general, they say nothing about the relative effects on different cell populations. As most immunosuppressive agents damage not only immunocytes but also other proliferating cell populations (myelopoietic cells, intestinal epithelium, &c.) we have to take the relative effects on different cell populations into account in therapy (Berenbaum 1969b). However, there are a few agents whose selectivity for a particular cell type is so great that only effects on these cells need be considered. Antilymphocyte serum (ALS) is one such agent, its effects on nonlymphoid cells usually being negligible. The doseresponse curve for ALS resembles that in Fig 2c (although its mechanism of action is quite different from that of antimetabolites). We would therefore expect that a limited amount of ALS would be more effective if divided into several small doses than if given as a single large dose. This expectation has been confirmed in experi-ments on antibody production and graft rejection in mice (Berenbaum et al. 1971) .
The analysis of dose-response curves of immunosuppressive, agents and their consequences has only just begun. Further study is likely to increase our understanding of the ways in which these agents act and enable us to use them more effectively. 
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Significance of Azathioprine Metabolites
In the treatment of acute leukemia and chronic granulocytic leukemia, azathioprine (Imuran) and 6-mercaptopurine (6-MP) have shown similar activity. However, as an immunosuppressant, azathioprine has shown some superiority, particularly in kidney transplants. Azathioprine was conceived as a slow-release form of 6-MP. Metabolic studies showed that the compound is split in vivo to release 6-MP (Elion et al. 1961 , Elion et al. 1962 , Elion et al. 1963 ). This has raised important questions. Is it an advantage for mercaptopurine to be released slowly and protected temporarily from catabolism? Are the pathways of metabolism of the two drugs different? Is there a locus of action for azathioprine which would not be expected of 6-MP? In..an attempt to answer these questions, metabolic studies were undertaken in man, in collaboration with Dr R W Rundles.
In the course of fifteen years of study of the metabolism of 6-MP (Elion et al. 1954 , Elion et al. 1963 , Elion 1967 , Hamilton. &.Elion 1954 we have.isolated and identified a.number of urinary metabolites. These compounds are methylated and oxidized derivatives of 6-MP. The principal metabolite is thiouric acid. Some of the sulphur is also split off as inorganic sulphate.
To determine how variable the metabolism of azathioprine may be, the fate of oral 35S-azathioprine was compared in three individuals. In each case, there was good absorption; over 50 % of the radioactive dose was excreted in the urine in 24 hours. There was also efficient splitting, since very little drug was excreted unchanged. A small amount of free 6-MP (equivalent to approximately 1 % of the dose) was excreted in each case. The amounts of thiouric acid varied from one patient to another, from 10 % to 25 % of the dose, and the amounts of inorganic sulphate ranged from 10 % to 20%. The differences from one individual to another were sufficiently great to indicate that a comparison of the metabolism of 6-MP and azathioprine was valid only in the same patient.
Comparison ofMetabolism of 35S-azathioprine and 35S-6-MP After the patient had received an oral dose of 100 mg 35S-azathioprine, the peak of radioactivity in the plasma occurred at 2 hours. The half-life of the radioactivity was 4 5-5 hours. After 10 hours, when the 35S was essentially all in the form of inorganic sulphate, clearance was much slower. The maximum amount of radioactivity in the plasma (at 2 hours) was equivalent to approximately 2 jig azathioprine per ml, but this represented all of the 35S-containing metabolites, not azathioprine alone. A similar picture was seen in this patient with 35S-6-MP (Elion 1969) .
A comparison was made of the various urinary metabolites following equivalent oral doses of 35S-6-MP and 35S-azathioprine. An attempt was made to account quantitatively for the radioactivity excreted, and the amount of each known metabolite was determined by isotope dilution in each urine sample, collected at 4-hour intervals during the first 24 hours. Azathioprine was absorbed somewhat better than 6-MP, 50 % of the radioactive dose being excreted in the urine in 24 hours, as opposed to 42 % when 35S-6-MP was given. The 48-hour stool specimens contained 12% of presumably unabsorbed material for azathioprine and 22 % for 6-MP. More free 6-MP, more thiouric acid and less inorganic sulphate were excreted after a dose of 6-MP than after azathioprine. When 6-MP was given, all of the 35S in the urine was accounted for as known metabolites. In the case of azathioprine, however, there was still about 12% of the urinary radioactivity unidentified. A bright yellow compound with a Amax=415 nm at pH 1 and 420 nm at pH 11 was observed during the column fractionations and was recognized as the compound which is formed when azathioprine is split with hydrogen sulphide, namely, 1-methyl-4-nitro-5-thioimidazole. Isotope dilution with a synthetic sample of this imidazole verified the fact that all the missing 35S was present in this form. Thus, azathioprine is split in vivo in two ways. In one, shown to occur also in vitro with hydrogen sulphide or glutathione, there is a nucleophilic attack on the methyl-nitroimidazole ring, with the release of 6-MP. In addition, some splitting occurs so as to leave the radioactive sulphur with the methyl-nitroimidazole ring. This type of splitting could result in a differential detoxification of the drug in particular tissues and might offer a possible explanation for the improved chemotherapeutic index of azathioprine.
Metabolism of 14C-azathioprine
The above studies with 35S-azathioprine did not reveal the fate of the bulk of the methylnitroimidazole moiety in vivo, since only a small portion was excreted as 1-methyl-4-nitro-5thioimidazole. It appeared likely that azathioprine might be subject to nucleophilic attack by nucleophiles other than sulphydryl groups. It was, therefore, important to study the fate of radioactive azathioprine in which methyl-nitroimidazole moiety was labelled.
Azathioprine (90 mg) labelled with 14C in the 4 and 5 carbons of the methyl-nitroimidazole ring (synthesized by Mrs H Yeowell) was administered orally to a patient (Elion et al. 1970 ). The radioactivity in this patient's plasma reached a peak at about 4 hours. At that time, the radioactivity was twice as high in the plasma as in the blood cells, but by 12 hours the radioactivity had equilibrated between cells and plasma. The disappearance of 14C from the blood was very much slower than it had been with 35S-azathioprine. At the end of 12 hours, there was still an amount of radioactivity equivalent to 0-10 ,ug azathioprine per ml of blood (corresponding to 40% of the peak value). Moreover, this level remained constant for approximately 36 hours.
The slow excretion of 14C was also evident in the urine. By 24 hours only 20% of the radioactivity had been excreted, and by 48 hours 37 %. This was in contrast to the 35S excretion which was 70 % after 48 hours. Thus, the methylnitroimidazole moiety remained in the body very much longer than the purine portion of the molecule.
The urine samples collected between 2 and 6 hours after drug administration were examined for 14C-containing metabolites. The samples were subjected to Dowex-1 (formate) chromatography and eluted with increasing concentrations of formic acid up to 6 N. Only 75 % of the 14C applied to the column was recovered, so that there probably were, in addition, some highly acidic metabolites which were not eluted with 6 N formic acid. Chromatography on a Dowex-50 (hydrogenion) column led to a recovery of 80 %. The radioactive compounds were further separated by paper chromatography. From the Dowex-1 eluates, evidence for 11 different compounds was obtained. In confirmation of the results obtained with 35S-azathioprine, there was essentially no unchanged azathioprine; between 2 and 10% of the imidazole moiety appeared as l-methyl-4nitro-5-thioimidazole. A very small amount of 8-hydroxyazathioprine was also detected.
Among the unknown 14C-containing metabolites were at least four with an ultraviolet absorption maximum in the 375-380 nm region at pH 1. It was apparent from this absorption maximum that the nitro group had not been reduced, since the reduction of the nitro group to an amino group moves the absorption maximum back to the 260-270 nm region. Of a number of synthetic derivatives examined, the compounds which most closely resembled the metabolites in question were 5-substituted amino-1-methyl-4nitroimidazoles, particularly the glycine and the histidine derivatives. Attempts to identify these unknown metabolites by mass spectrometry failed.
To determine whether an amino acid, such as glycine, would react with the methyl-nitroimidazole moiety of azathioprine in vivo, rats were given non-radioactive azathioprine, 50 mg/kg, and an equimolar dose of 14C-glycine (DeMiranda & Chu 1970) . The urine was fractionated on a Dowex-l (formate) column. One radioactive metabolite, after considerable purification by paper chromatography, was shown to have an ultraviolet absorption spectrum and chromatographic behaviour in three solvent systems identical with that of synthetic 1-methyl-4-nitro-5-carboxymethylaminoimidazole. It was thus apparent that azathioprine had indeed reacted with the radioactive glycine under in vivo conditions, and that the glycyl group had become attached to the methyl-nitroimidazole ring.
Discussion
What can account for the favourable features of azathioprine in comparison with 6-MP? Since both are effective immunosuppressants, there is still validity in the original thesis that azathioprine may serve as a slow release form of 6-MP. It is difficult, however, to obtain the direct data to show that 6-thioinosinic acid is formed to a greater extent or more selectively in lymphocytes. The methodology for the determination of minute quantities of azathioprine metabolites in plasma and in the lymphocytes themselves is only now being developed. With the recent use of liquid chromatography, we may be able to detect materials in the blood which have not hitherto been detectable and which do not appear in urine, either because they are unstable or because they do not pass cell membranes without alteration.
What characteristics of azathioprine itself may be distinctive? It is apparent that azathioprine is subject to nucleophilic attack by amino groups as well as sulphydryl compounds. It also appears to be split partially between the purine ring and the sulphur, although the major portion of the sulphur remains bound to the purine. It still remains to be determined whether these reactions occur preferentially in specific tissues. It is conceivable that the amino and sulphydryl groups which react with azathioprine are portions of polypeptides or large molecular weight proteins and possibly cell membranes. Such reactions could cover up antigenic sites or recognition sites on a protein, and this might provide a mechanism of action for azathioprine over and above its conversion to 6-MP.
Studies on the urinary metabolites of azathioprine do not answer all the important questions about this drug. Bach et al. (1969) have reported the strong inhibitory effect of azathioprine on rosette formation. We have tested the urinary metabolites of azathioprine for their inhibition of rosette formation but have found none, including 6-MP, to be as active as azathioprine. In patients with severe liver disease, the immunosuppressive activity of the plasma following azathioprine administration has been reported to be much lower than in normal patients (Bach & Dardenne 1970 , Mitchell et al. 1970 ). Nevertheless, the urinary metabolites of azathioprine in 2 such patients, studied by us in collaboration with Professor Roger Williams, do not significantly differ from those in other patients.
New knowledge of the biochemical events basic to the immune response and remarkably sensitive new analytical techniques encourage us to further studies of azathioprine. Led through a metabolic maze by following azathioprine and its metabolites, we anticipate finding means to understand better the regulation of the immune response and, at the same time, to develop other useful immunosuppressant drugs. Elion G B, Bieber S & Hitchings G H (1954) Azathioprine (Imuran) is one of the most widely used immunosuppressants. Chemical studies have shown that the metabolism of the drug is complex: more than ten metabolites have been isolated and it is thought that more exist. The role of each metabolite present in serum in the biological activity of azathioprine and the interactions between them have not been determined. Bioassays provide an index of the activity present in the serum after drug administration. Chemical methods are usually preferred to bioassays for evaluation of the serum concentration of drugs because bioassays generally do not discriminate between metabolites, and the significance of the activity evaluated is thus difficult to assess. However, when chemical methods are not available, reproducible serum bioassays may prove useful for the clinical management of drugs in normal and pathological conditions, as has been demonstrated extensively for antibiotics.
We have proposed (Bach, Dardenne & Fournier 1969 ) the rosette inhibition test as a precise and RIA sensitive in vitro bioassay for immunosuppressive agents. This assay is based on the inhibition by such agents of rosette formation by normal lymphocytes. The present paper reviews the data obtained using this assay for azathioprine in normal subjects and in patients with liver diseases. We showed (Bach & Dardenne 1969 in 6 cases that no rosette-inhibiting activity (RIA) appeared in the serum of patients with,severe liver disease after azathioprine administration. In this paper we have extended our study to 18 subjects with various liver diseases, and compared the results with those obtained in normal subjects. The blood level of 35S-labelled azathioprine was studied in 6 normal subjects and in 6 patients with liver diseases along with the rosette inhibition test. Recently, Mitchell et al. (1970) have confirmed our findings in patients with, hepatic failure after liver transplantation.
Material and Methods
Determination of serum RIA: Serum samples are heated to 56°C for 30 min and absorbed with sheep red blood cells to eliminate natural antisheep haemagglutinins which prevent accurate microscopic evaluation of the rosettes. Such absorption does not modify the RIA. Reproducibility is good (Fig 1) : repeated RIA evaluations on one sample are always within one log2 dilution of the mean. We have recently used a simpler method to remove heemagglutinins, which is to filter the serum samples on an Amicon ultrafilter (cut-off=50,000 mol. wt.). No differences have been found between RIAs measured after filtration or absorption.
Kinetics of 35S-labelled azathioprine: 35S-labelled azathioprine (kindly donated by Dr G B Elion, Burroughs Wellcome, North Carolina) was used in some of the subjects (7 normal subjects, 4 patients with cirrhosis, 3 with hepatitis). The specific activity was 2,100 d/min per ,ug; 100 pCi was administered orally in all cases and carriercold azathioprine was added for each dose (3 mg/kg). The radioactivity of serum samples was determined, taking into account the quenching of the preparation.
Patients: Sixteen normal subjects and 19 patients with liver diseases took orally 3 mg/kg per day azathioprine in a single dose. The serum was collected before and at several periods after drug administration (15 min, 30 min, 1, 2, 4, 12, 24 and 48 h). The RIA and the radioactivity (when 35Slabelled azathioprine was used) were determined for each sample. In 3 normal subjects and in 3 patients with liver diseases, 6-mercaptopurine (6-MP) was given at a dose of 1-5 mg/kg. The patients with liver diseases included: 9 cirrhosis, 4
